Dermata Therapeutics Inc
NASDAQ:DRMA
Income Statement
Earnings Waterfall
Dermata Therapeutics Inc
Income Statement
Dermata Therapeutics Inc
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(3)
|
(4)
|
(4)
|
(6)
|
(8)
|
(8)
|
(10)
|
(11)
|
(10)
|
(9)
|
(8)
|
(8)
|
(8)
|
(9)
|
(10)
|
(12)
|
(13)
|
(12)
|
(11)
|
(9)
|
|
| Selling, General & Administrative |
(2)
|
(3)
|
(3)
|
(3)
|
(4)
|
(4)
|
(5)
|
(5)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
|
| Research & Development |
(2)
|
(1)
|
(2)
|
(2)
|
(3)
|
(4)
|
(5)
|
(6)
|
(6)
|
(5)
|
(4)
|
(4)
|
(4)
|
(4)
|
(6)
|
(7)
|
(8)
|
(8)
|
(6)
|
(5)
|
|
| Operating Income |
(3)
N/A
|
(4)
-25%
|
(4)
-14%
|
(6)
-26%
|
(8)
-39%
|
(8)
-7%
|
(10)
-17%
|
(11)
-8%
|
(10)
+8%
|
(9)
+5%
|
(8)
+11%
|
(8)
+8%
|
(8)
-7%
|
(9)
-12%
|
(10)
-13%
|
(12)
-14%
|
(13)
-9%
|
(12)
+7%
|
(11)
+10%
|
(9)
+14%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(3)
N/A
|
(4)
-27%
|
(5)
-12%
|
(6)
-24%
|
(8)
-38%
|
(8)
-6%
|
(10)
-17%
|
(10)
-7%
|
(10)
+8%
|
(9)
+6%
|
(8)
+11%
|
(7)
+9%
|
(8)
-6%
|
(9)
-11%
|
(10)
-13%
|
(11)
-15%
|
(12)
-9%
|
(11)
+7%
|
(10)
+10%
|
(9)
+14%
|
|
| Net Income | |||||||||||||||||||||
| Income from Continuing Operations |
(3)
|
(4)
|
(5)
|
(6)
|
(8)
|
(8)
|
(10)
|
(10)
|
(10)
|
(9)
|
(8)
|
(7)
|
(8)
|
(9)
|
(10)
|
(11)
|
(12)
|
(11)
|
(10)
|
(9)
|
|
| Net Income (Common) |
(3)
N/A
|
(4)
-27%
|
(5)
-12%
|
(8)
-79%
|
(10)
-26%
|
(14)
-29%
|
(15)
-10%
|
(13)
+12%
|
(10)
+26%
|
(9)
+6%
|
(8)
+11%
|
(7)
+9%
|
(8)
-6%
|
(9)
-11%
|
(10)
-13%
|
(11)
-15%
|
(12)
-9%
|
(11)
+7%
|
(10)
+10%
|
(9)
+14%
|
|
| EPS (Diluted) |
-932.7
N/A
|
-1 187.37
-27%
|
-1 334.4
-12%
|
-3 994.32
-199%
|
-3 015.76
+24%
|
-3 881.69
-29%
|
-3 198.94
+18%
|
-2 550.09
+20%
|
-2 089.32
+18%
|
-1 379.74
+34%
|
-445.68
+68%
|
-344.79
+23%
|
-399.72
-16%
|
-13.04
+97%
|
-145.08
-1 013%
|
-72.49
+50%
|
-80.32
-11%
|
-22.22
+72%
|
-10.06
+55%
|
-8.61
+14%
|
|